Details of the Drug

General Information of Drug (ID: DM09YTN)

Drug Name
Abelacimab
Synonyms MAA868
Indication
Disease Entry ICD 11 Status REF
Atrial fibrillation BC81.3 Phase 2 [1]
Drug Type
Monoclonal antibody
Cross-matching ID
UNII
KX1N4TV7UY
DrugBank ID
DB16682
TTD ID
D9DWC6

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor XI (F11) TTJCPUT FA11_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04755283) A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation (AZALEA). U.S.National Institutes of Health.
2 Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost. 2022 Feb;20(2):307-315.